Study of YKST02 for relapsed or refractory multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma and have tried at least two different types of myeloma treatments (like immunomodulatory drugs, proteasome inhibitors, or anti-CD38 drugs).
- Your myeloma is still active and measurable (for example, a certain level of M-protein in blood or urine).
- You are able to take care of yourself (ECOG score 0–1) and are expected to live at least 12 more weeks.
- You have not had a prior treatment that targets BCMA (like CAR-T or a bispecific antibody).
- You do not have serious heart problems, uncontrolled infections, or other major medical conditions that would make the trial unsafe.
- You are willing to use effective contraception if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
This trial tests a new drug called MBS314 for people whose multiple myeloma has returned or stopped responding to other treatments. The goal is to see if MBS314 can help shrink or control the myeloma.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This trial tests an investigational drug called YKST02 for people with multiple myeloma that has returned or not improved after at least two prior treatments. The goal is to see if YKST02 can help control the cancer.
This trial tests an investigational drug called KIV-318 for people with multiple myeloma that has come back or not responded to standard treatments. It aims to see if KIV-318 is safe and effective in targeting a protein called BCMA on myeloma cells.
This trial tests a new drug, SHR-5421, for people with multiple myeloma that has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.